ENTA Enanta Pharmaceuticals, Inc.
USHealthcareAs of 2026-08-24
Why ENTA matters now
Enanta Pharmaceuticals, Inc. (ENTA) is a US stock in Healthcare. The latest InvestLog snapshot shows $14.10 with +4.68% on the session and $410.0M in market capitalization; recent performance reads 1-month -7.99% and YTD -19.72%.
The latest financial table shown here is Q2 2026, with revenue of $17.2M, net income of $-13.1M, and EPS of $-0.45. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.3%.
The latest indexable market news headline is "Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $54.00; recent insider activity includes CARTER BRUCE L A filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.32
P/S
4.25
EV/EBITDA
-9.57
DCF Value
$-60.97
FCF Yield
-3.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.3%
Operating Margin
-87.2%
Net Margin
-89.6%
ROE
-64.0%
ROA
-19.7%
ROIC
-19.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $17.2M | $-13.1M | $-0.45 |
| Q1 2026 | $18.6M | $-11.9M | $-0.56 |
| Q4 2025 | $15.1M | $-18.7M | $-0.87 |
| FY 2025 | $65.3M | $-81.9M | $-3.84 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$48.20
Target (Median)
$54.00
Target Range
$20.00 - $87.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.99
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.